Confirmatory Study 3 of KPS-0373 in Patients With Spinocerebellar Degeneration

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase III study to evaluate the efficacy and safety of KPS-0373 given once daily after breakfast in 142 patients with spinocerebellar degeneration . This study consists of the 4-week screening period, 24-week treatment period, and 4-week follow-up period.

NCT Number	NCT07040137
Lead Sponsor	Kissei Pharmaceutical Co., Ltd.
Conditions	Spinocerebellar Degeneration
Enrollment	142 participants
Start Date	2025-07
Primary Completion	2027-03-31 (estimated)
Study Completion	2027-03-31 (estimated)
Updated on ClinicalTrials.gov	2025-06-27